PLRZ•benzinga•
Polyrizon Announced Preliminary Safety Study For A Formulation Of Its PL-14 Allergy Blocker, Conducted On Fully Differentiated Human Nasal Tissue Using The Mucilair Model, The Study Demonstrated Strong Local Tolerability
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 25, 2025 by benzinga